Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23736080 | 0.93 | HDAC3 (0.34) | GAAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL15344705 | 0.92 | — | — | |
| SCHEMBL15727144 | 0.89 | PDE4B (0.34) | GAAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL26481205 | 0.89 | HDAC3 (0.33) | GAAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL806626 | 0.88 | CCNT1 (0.33) | PDE4B | |
| SCHEMBL15344732 | 0.88 | TUBB4A (0.30) | — | |
| SCHEMBL14234971 | 0.87 | PDE4A (0.33) | GAAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23736038 | 0.85 | IARS1 (0.31) | — | |
| SCHEMBL806768 | 0.83 | HDAC3 (0.33) | GAAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL15727211 | 0.82 | CCNT1 (0.35) | PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160297851-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2016-10-13 | — | — | US | disclosed |
| US-9187524-B2 | Broad spectrum antibiotic arylomycin analogs | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150045286-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2015-02-12 | — | — | US | disclosed |
| WO-2014081886-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20130281360-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | THE SCIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2013138187-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2012036907-A2 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | ROMESBERG FLOYD E (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045286-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | SPAST, NPEPPS, SPATS2L | GAA 259/4885HDAC3 2912/4885HDAC4 3043/4885 |
| US-20130281360-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | SPAST, NPEPPS, SPATS2L | GAA 259/4885HDAC3 2912/4885HDAC4 3043/4885 |
| US-20160297851-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | SPAST, NPEPPS, SPATS2L | GAA 259/4885HDAC3 2912/4885HDAC4 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.